These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 35495604)

  • 1. Immunological signature of chronic spontaneous urticaria (Review).
    Dobrican CT; Muntean IA; Pintea I; Petricău C; Deleanu DM; Filip GA
    Exp Ther Med; 2022 Jun; 23(6):381. PubMed ID: 35495604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis of chronic urticaria: an overview.
    Jain S
    Dermatol Res Pract; 2014; 2014():674709. PubMed ID: 25120565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologics for the Use in Chronic Spontaneous Urticaria: When and Which.
    Maurer M; Khan DA; Elieh Ali Komi D; Kaplan AP
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1067-1078. PubMed ID: 33685605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.
    Chang TW; Chen C; Lin CJ; Metz M; Church MK; Maurer M
    J Allergy Clin Immunol; 2015 Feb; 135(2):337-42. PubMed ID: 24948369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic urticaria and thyroid pathology.
    Gonzalez-Diaz SN; Sanchez-Borges M; Rangel-Gonzalez DM; Guzman-Avilan RI; Canseco-Villarreal JI; Arias-Cruz A
    World Allergy Organ J; 2020 Mar; 13(3):100101. PubMed ID: 32180891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn's Disease.
    Barni S; Giovannini M; Liccioli G; Sarti L; Gissi A; Lionetti P; Mori F
    Front Immunol; 2021; 12():635069. PubMed ID: 33737936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urticaria and Angioedema: an Update on Classification and Pathogenesis.
    Radonjic-Hoesli S; Hofmeier KS; Micaletto S; Schmid-Grendelmeier P; Bircher A; Simon D
    Clin Rev Allergy Immunol; 2018 Feb; 54(1):88-101. PubMed ID: 28748365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease.
    Martina E; Diotallevi F; Bianchelli T; Paolinelli M; Offidani A
    Curr Pharm Biotechnol; 2021; 22(1):32-45. PubMed ID: 32603278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
    Kaplan AP; Giménez-Arnau AM; Saini SS
    Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenic intracellular and autoimmune mechanisms in urticaria and angioedema.
    Altman K; Chang C
    Clin Rev Allergy Immunol; 2013 Aug; 45(1):47-62. PubMed ID: 22674016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Justification for IgE as a therapeutic target in chronic spontaneous urticaria.
    Sánchez-Borges M; Capriles-Hulet A; Caballero-Fonseca F; González-Aveledo L
    Eur Ann Allergy Clin Immunol; 2017 Jul; 49(4):148-153. PubMed ID: 28752717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.
    Giménez-Arnau AM
    Expert Opin Biol Ther; 2017 Mar; 17(3):375-385. PubMed ID: 28125304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relevance of the Basophil High-Affinity IgE Receptor in Chronic Urticaria: Clinical Experience from a Tertiary Care Institution.
    Deza G; March-Rodríguez A; Sánchez S; Ribas-Llauradó C; Soto D; Pujol RM; Gimeno R; Giménez-Arnau AM
    J Allergy Clin Immunol Pract; 2019; 7(5):1619-1626.e1. PubMed ID: 30685572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both.
    Chen Y; Yu M; Huang X; Tu P; Shi P; Maurer M; Zhao Z
    World Allergy Organ J; 2021 Jan; 14(1):100501. PubMed ID: 33510832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of FcεRI-bearing leucocytes to omalizumab in chronic spontaneous urticaria.
    Alizadeh Aghdam M; Knol EF; van den Elzen M; den Hartog Jager C; van Os-Medendorp H; Knulst AC; Otten HG; Röckmann H
    Clin Exp Allergy; 2020 Mar; 50(3):364-371. PubMed ID: 31925825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab may not inhibit mast cell and basophil activation in vitro.
    Gericke J; Ohanyan T; Church MK; Maurer M; Metz M
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1832-6. PubMed ID: 25257818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers In Chronic Spontaneous Urticaria: Current Targets And Clinical Implications.
    Puxeddu I; Petrelli F; Angelotti F; Croia C; Migliorini P
    J Asthma Allergy; 2019; 12():285-295. PubMed ID: 31571935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inducible urticaria and chronic spontaneous urticaria].
    Du Thanh A
    Ann Dermatol Venereol; 2014 Nov; 141 Suppl 3():S570-9. PubMed ID: 25539678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved FcεRI-Mediated CD203c Basophil Responsiveness Reflects Rapid Responses to Omalizumab in Chronic Spontaneous Urticaria.
    Oda Y; Fukunaga A; Washio K; Imamura S; Mizuno M; Hatakeyama M; Ogura K; Nishigori C
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1166-1176.e8. PubMed ID: 32898709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.
    Jörg L; Pecaric-Petkovic T; Reichenbach S; Coslovsky M; Stalder O; Pichler W; Hausmann O
    Clin Exp Allergy; 2018 Feb; 48(2):196-204. PubMed ID: 29164723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.